Teva Israel and Syqe Medical have announced that Teva will distribute Syqe’s cannabis inhaler in Israel, with Syqe responsible for manufacturing the inhaler and cartridges. No financial terms were disclosed.
The Syqe device delivers 100 mcg doses using heat and controlled air flow plus cartridges filled with “structurally modified” raw plants. According to Teva, the device has been used for more than a year at the Rambam Hospital in Haifa and, once approved by the Ministry of Health, will be made available for home use by Teva.
Globes, an Israeli financial daily, quoted Teva Israel CEO Avinoam Sapir saying that “. . . groundbreaking medical devices – such as the ones developed by Syqe Medical, which generate therapeutical value for both patient and medical staff – fit well into the strategy of Teva Israel . . . “.
https://twitter.com/SyqeMed/status/803186762482941952
